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Human parvovirus B19 has a nonenveloped, icosahedral capsid packaging a linear single-stranded DNA genome of 5.6 kb with long
inverted terminal repeats (ITR) at both the 5V and 3V end. Previous attempts to construct a full-length B19 clone were unsuccessful due to
deletions in the ITR sequences. We cloned the complete parvovirus B19 genome with intact ITRs from an aplastic crisis patient. Sequence
analysis of the complete viral genome indicated that both 5V and 3V ITRs have two sequence configurations and several base changes within
the ITRs compared to previous published sequences. After transfection of the plasmid into permissive cells, spliced and non-spliced viral
transcripts and viral capsid proteins could be detected. Southern blot analysis of the DNA purified from the plasmid-transfected cells
confirmed parvovirus B19 DNA replication. Production of infectious virus by the B19 plasmid was shown by inoculation of cell lysate
derived from transfected cells into fresh cells. Together, these results indicate the first successful production of an infectious clone for
parvovirus B19 virus.
Published by Elsevier Inc.Keywords: Parvovirus B19; Complete sequence; Infectious clone; Erythrovirus; Viral DNA replication; Inverted terminal repeatsIntroduction
Parvovirus B19 is the only member of the Parvoviridae
family known to cause disease in humans. Infection typically
causes fifth disease in children, polyarthropathy syndromes
in adults, transient aplastic crisis in patients with underlying
chronic hemolytic anemia, and chronic anemia due to per-
sistent infection in immunocompromised patients. Infection
during pregnancy can lead to hydrops fetalis with possible
fetal loss or congenital infection (Brown et al., 1994b).
Disease due to parvovirus B19 is mainly caused by a
cytotoxic effect on erythroid progenitor cells in bone marrow,
with interruption of erythrocyte production. The physiolog-
ical conditions of the host and the extent of the immune
antiviral response then contribute to the evolution and clinical
manifestation of the infection (Heegaard and Brown, 2002).0042-6822/$ - see front matter. Published by Elsevier Inc.
doi:10.1016/j.virol.2003.09.011
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E-mail address: zhin@nhlbi.nih.gov (N. Zhi).In common with other parvoviruses, B19 has a small (22
nm), nonenveloped, icosahedral capsid packaging a single-
stranded DNA genome of approximately 5600 nucleotides.
The ends of the genome are long inverted terminal repeats
(ITR) of 383 nucleotides long, of which the distal 365
nucleotides form an imperfect palindrome (Deiss et al.,
1990). Transcription of the B19 viral genome is controlled
by the single promoter (p6) located at map unit 6, and
regulates the synthesis of all nine viral transcripts (Blundell
et al., 1987; Doerig et al., 1990; St Amand et al., 1991).
There is a single non-spliced transcript for the production of
the nonstructural protein (NS), and the other eight tran-
scripts by a combination of different splicing events encode
the two capsid proteins (VP1 and VP2) and two smaller
proteins of unknown function (Cotmore et al., 1986; Luo
and Astell, 1993; Ozawa et al., 1987).
Parvovirus B19 exhibits a selective tropism for erythroid
progenitor cells, and can only be cultured in erythroid
progenitor cells from bone marrow (Ozawa et al., 1986),
fetal liver (Brown et al., 1991; Yaegashi et al., 1989), or
rare cell lines such as UT7/Epo (Komatsu et al., 1993;
Shimomura et al., 1992) or KU812Ep6 (Miyagawa et al.,
1999). The selective tropism of the virus is mediated in part
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lineage, the neutral glycolipid globoside (blood group P
antigen) (Brown et al., 1993). Previously, we have shown
that P antigen-negative erythrocytes cannot be hemaggluti-
nated and that human bone marrow cells that lack globo-
side on the cell surface are resistant to B19 infection
(Brown et al., 1994a). The tissue distribution of globoside
(von dem Borne et al., 1986) correlates with the tropism of
B19 and its presence on cell surface is thus a major
determinant of viral tropism. Intracellular factors, possibly
specific for the erythroid lineage, are also required for
complete expression of viral genome and for viral infec-
tivity (Liu et al., 1992).
Here, we report the construction of an infectious clone
parvovirus B19. The full-length B19 genome, including
complete ITR sequences at both 5V and 3V ends, was cloned
and sequenced. Transfection of the clone into permissive
cells led to the production of viral transcripts, DNA repli-
cation, and the production of infectious virus.Results
Sequencing the full-length genome of parvovirus B19 and
characterization of the ITR
First, the complete B19 coding region, including half
of each ITR, was amplified using PCR. Although severalFig. 1. Schematic representation of the experimental strategy for construction
constructed in the present study (B). (B1) Plasmid pB19-N8 contains 4844 nucleot
flanked by two EcoRI sites includes the entire coding region and 177 nucleotides o
B19 genome in pProEX HTb vector, and the B19 sequence is flanked by two SalI
EcI36II digestion to remove the undesired XbaI site. (B4) Plasmid pB19-M20 that
generate DdeI site in the B19 genome. The arrows indicate the genes in either the
B19 genome indicate the ITR sequences.plasmids containing the B19 genome were obtained, only
one clone, obtained using the primer B19-187FR, did not
contain deletions. This plasmid, designated as pB19-N8
(Fig. 1B1), was sequenced (GenBank AY386330), and
contained a 4844-nucleotide sequence including the entire
coding region, and 177 nucleotides of the ITR. The
nucleotide sequence of this B19 isolate (J35) had
99.1% similarity to that of B19-Au isolate (GenBank
M13178). The putative NS, VP1, and VP2 capsid pro-
teins had 99.4%, 99.4%, and 99.6% homology, respec-
tively, at the amino acid level compared to the B19-Au
isolate.
The sequence of the complete ITRs was obtained with
primers based on the sequence of the pB19-N8 and the
predicted start sequence of the ITR. Analysis of the sequen-
ces indicated that both the 5V and 3V ITRs were identical, and
were present in two different configurations analogous to
the flip and flop formats previously reported (Deiss et al.,
1990) (Fig. 2).
Cloning of the full-length B19 genome
Attempts to construct a full-length clone by ligating the
ITR sequences to pB19-N8 were repeatedly unsuccessful.
As B19 packages equal numbers of both positive and
negative DNA strands (Summers et al., 1983), and has a
unique BamHI restriction enzyme site in the genome
(Cotmore and Tattersall, 1984), these properties were usedof infection clone of B19 parvovirus (A) and the recombinant plasmids
ides of B19 genome in pCR-Blunt II TOPO vector. The B19 fragment that is
f the ITR. (B2) Plasmid pB19-4244 contains 5592 nucleotides of full-length
sites. (B3) Plasmid pB19-4244d was modified from pB19-4244 by XhoI –
was derived from pB19-4244d contains the site of mutagenesis (C2285T) to
B19 genome or vectors, and the shaded circles at both 5V and 3V ends of the
Fig. 2. Structure and comparison of terminal inverted repeats in different parvovirus B19 isolates. (A) Structure of the B19 terminal presented in its hairpin
form. The flip and flop orientations at the 5V end (+ strand) are shown. The numbers indicate the nucleotide positions in the viral genome of B19-J35 isolate. (B)
Comparison of nucleotide sequences of the ITRs in different B19 isolates. Aligned positions of different nucleotides are shown by white characters on a black
background, and the gaps indicated by dashed lines are introduced to optimize alignment of all sequences. The numbers on the right indicate the positions of
nucleotides in the genomes of respective B19 isolates.
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1A). Of the 192 clones that were analyzed, five contained
the untruncated 5V end of the genome, and two clones
contained the untruncated 3V end of the genome. All the
untruncated clones had the same ‘‘flip’’ format for their
ITRs (Fig. 2).
After ligation of the plasmids together, two identical
clones consisting of the full-length B19 genome were
selected and designated as B19-36 and pB19-4244 (Fig.
1B2). These full-length clones were sequenced and thesequences of inserts showed 100% identity to the
corresponding region in the pB19-N8. The full viral genome
was 5592 nucleotides long, with terminal repeat sequences
of 381 nucleotides that formed an imperfect palindrome. In
comparison to the previously published sequences (Deiss et
al., 1990), and the one unpublished sequence in GenBank
(B19-HV; AF162273), there were two less nucleotides at the
start and end of the genome, resulting in a palindromic
sequence of 361. As showed in Fig. 2B, the nucleotide
sequences of the flip and flop are slightly different from that
Fig. 3. Detection of the B19 transcripts and capsid proteins in the UT7/Epo-
S1 cells transfected with recombinant plasmids or infected with B19 virus.
(A) RT-PCR analysis of the B19 transcripts. The total RNAs were extracted
from the UT7/Epo-S1 cells at 72 h post-transfection or post-infection. The
PCR was performed with a primer pair of B19-1 and B19-9. The products
were analyzed by agarose gel electrophoresis and Southern blotting with an
alkaline-phosphatase-labeled probe. (+) and ( ) indicate the presence or
absence of the reverse transcriptase in the reaction, respectively. The
numbers on the right indicate the respective amplicon size. (B) Detection of
the B19 capsid proteins by indirect fluorescent antibody assay. The UT7/
Epo-S1 cells were infected with B19 virus (B1) or transfected with the
pB19-M20 (B2) or pB19-N8 (B3). At 72 h post-infection or post-
transfection, the capsid proteins were detected by using monoclonal
antibody 521-5D, and fluorescein isothiocyanate-labeled goat anti-mouse
IgGs used as secondary antibodies. Magnification 750.
N. Zhi et al. / Virology 318 (2004) 142–152 145reported by Deiss et al. (1990), but the numbers and
positions of the unpaired nucleotides in these palindromic
sequences are conserved between the two different B19
isolates.We tested whether the full-length B19 genome, especial-
ly the ITR sequences, were able to be stabilized in the
plasmid backbone during the multiple steps of molecular
cloning experiments. The plasmid pB19-4244 were digested
with BamHI and religated, and then transformed into
bacteria Sure2. After incubation at 30jC overnight, 18
colonies were picked up from the plate and the bacteria
were propagated at 30jC. The plasmids were purified and
mapped with restriction digestion with HindIII, BssHII, and
SalI. We found that all of the 18 plasmids tested had the
correct restriction sites, and specifically, there were no
deletions in the hairpin sequences (data not shown). This
was also confirmed by serially passaging the plasmids and
sequencing the hairpins. We found no evidence of deletions
under the conditions used in the present study.
Construction of a variant infectious clone
Although the cloned sequence was 99% identical to the
B19-Au sequence, it was observed that there was a single
nucleotide difference between the J35 sequence (and B19-
Au) and the published sequence of another isolate B19-Wi
(GenBank M24682) that would convert a BsrI site in J35
to a DdeI site. This site was within the RT-PCR product
amplified with the primer pair of B19-2255 and B19-2543
and could potentially be used to distinguish transcripts and
hence viruses with the different sequence. We therefore
constructed a second plasmid, pB19-M20 (Fig. 1B4),
which contained the identical full-length clone, but in
which the cytosine at the nucleotide of 2285 was replaced
by thymine.
Transfection of full-length B19 genome into UT7/Epo-S1
cells
The plasmid pEGFP-F was used to optimize the con-
ditions for transfecting UT7/Epo-S1 cells. Although stan-
dard electroporation and liposomes were tried, the best
results were obtained using the AMAXA Cell Line Nucle-
ofector system. The highest transfection efficiency (f70%)
with minimum cytotoxicity (f20%) was achieved with
reagent R and T-20 program using 3 Ag pEGFP DNA and
2  106 UT7/Epo-S1 cells, following the manufacturer’s
instructions.
UT7/Epo-S1 cells were transfected with plasmids pB19-
4244, pB19-M20, and pB19-N8 under the same condi-
tions, and harvested at 72 h post-transfection. The RT-PCR
and immunofluorescence assay were performed to detect
the viral spliced transcripts and capsid proteins. After RT-
PCR, two amplicons of 253 and 133 bp, representing the
alternative spliced transcripts of B19 capsid gene, were
detected in the cells transfected with either plasmid (Fig.
3A). By immunofluorescence assay, B19 capsid protein
was also detected in the transfected cells, with f15% of
the cells having a positive signal when transfected with
pB19-4244 and (Fig. 3B2) and 5% with pB19-pN8 (Fig.
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positive cells between the two different plasmid constructs
although the same amount of plasmid DNA was introduced
into the cells under identical conditions. Infection with
B19 wild-type virus (J35 isolate) gave f20% positive
cells (Fig. 3B1).
Excision of B19 genome from the plasmid after transfection
into permissive cells
During the replication of parvovirus B19, the viral
single-stranded DNA is converted to a double-stranded
replicative form which has either an ‘‘extended’’ or a
‘‘turnaround’’ form at the terminal regions. These interme-
diate structures provide evidence for viral DNA replication
and can be distinguished by BamHI restriction enzyme
digestion (Cotmore and Tattersall, 1984) (Fig. 4A). To test
whether the B19 genome inserted in pB19-4244 could be
excised from the flanking vector sequences and produce
progeny viral DNA, we compared Southern blot analysis of
the DNA purified from the cells transfected with either
plasmids cut with SalI enzyme (which releases the full-
length B19 genome from the plasmid, Fig. 1B2) or intact
plasmids. At 72 h post-transfection, the DNA was extracted
from the cells and incubated with the restriction endonucle-
ase EcoRI (no cuts in the parvovirus B19 genome) or
BamHI (a single cut in the parvovirus genome). As in
B19 infection of UT7/Epo-S1 cells, distinct doublets of
1.5 and 1.4 kb were detected in all the transfected cellFig. 4. (A) Schematic representation of the replication of B19 viral genome and (B
(B). (B1) The DNA was purified from the UT7/Epo-S1 cells transfected with Sa
digested fragment of the plasmid pB19-4244 or pB19-pM20. (B3) The DNAwas p
M20. In the experiments, the DNA from the cell infected with B19 virus was used
the fragments separated by agarose electrophoresis, transferred to a nylon membr
coding region. The numbers on the left indicate molecular size in kilobase.samples digested with BamHI, but not in the plasmid
controls (Figs. 4B1, B2, and B3). Although some of the
signals at 4.1- and 1.5-kb bands, in Fig. 4B1, would have
been contributed by the transfected DNA, the 1.4-kb band,
however, is a definitive marker for viral genome replication.
In addition, a band with a molecular size of 5.6 kb, which
corresponds to the size of the viral B19 genome, was
detected in EcoRI-digested DNA from the cells transfected
with undigested (SalI) plasmid pB19-M20 (Fig. 4B3). This
indicated that progeny viral DNA was produced because
neither the B19 genome nor vector contains an EcoRI
restriction enzyme site. Although equal amounts of DNA
of either SalI-digested plasmid or whole plasmid were
introduced into the cells, the band density of the replication
intermediates in the sample of SalI-digested fragment
appeared to be stronger. This suggested that the replication
process was facilitated when the viral genome was released
from the vector backbone.
Production of infectious virus
To determine if infectious virus was generated from the
cells transfected with plasmid pB19-4244 or pB19-M20,
we used the supernatant prepared from the cell lysates of
transfected cells to infect UT7/Epo-S1 cells, and used the
detection of spliced transcripts of viral capsid genes by the
RT-PCR as a marker for successful viral infection. Plasmid
pB19-N8, which does not contain intact ITRs and should
not produce infectious virus, was used as a negative) detection of B19 parvovirus genome replication by Southern blot analysis
lI-digested fragment of the plasmid pB19-4244 or pB19-pM20. (B2) SalI-
urified from the UT7/Epo-S1 cells transfected with whole plasmid of pB19-
as a positive control. Purified DNAwas digested with BamHI or EcoRI and
ane, and hybridized with a 32P-random-primed probe of the complete B19
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positive control. As observed previously, following trans-
fection, spliced transcripts were detected in all the samples
including cells transfected with pB19-N8 (Fig. 3A). Im-
mediately after inoculation of the clarified supernatant into
the UT7/Epo-S1 cells, no RT-PCR product was detected in
any of the samples (Fig. 5A1), indicating that there was no
carry-over of the RNA from the transfected cells. At 72
h post-inoculation, spliced transcripts were detected in the
samples derived from the cells transfected with pB19-4244
and pB19-M20, but not with pB19-N8 (Fig. 5A2), con-
firming that the full-length viral genome containing com-
plete ITRs is essential for generation of infectious viral
particles. In addition, no viral transcripts were detected in
cells in which the plasmids were directly incubated with
the cells (no electroporation) (Fig. 5A2), suggesting that
the detection of transcripts in the cells inoculated with
transfected cell lysate was due to the production of
infectious B19 virus from the plasmid.
The infected cultures were also examined for the
production of parvovirus B19 capsid proteins. At 72
h post-inoculation, capsid proteins could be detected in
the nuclei and cytoplasm of cells with the supernatants
derived from either B19 infection or pB19-M20 transfec-
tion (Figs. 5B1 and B2), but not in the cells inoculated
with either pB19-N8 cell lysate (Fig. 5B3) or directly withFig. 5. Detection of the B19 transcripts and capsid proteins in the UT7/Epo-S1 cells
infected with B19 virus. (A) RT-PCR analysis of the B19 transcripts. At 72 h pos
thawing, and the clarified supernatant from B19-infected, or pB19-N8- or pB19-
extracted from the UT7/Epo-S1 cells at 0 h (A1) and 72 h (A2) post-infection. The
were analyzed by agarose gel electrophoresis and Southern blotting with an alkalin
the reverse transcriptase in the reaction, respectively. The numbers on the right ind
by indirect fluorescent antibody assay. At 72 h post-inoculation, the viral capsid
derived from the cell infected with B19 (B1), or transfected with pB19-M20 (B2
isothiocyanate-labeled goat anti-mouse IgG were used as secondary antibody. Maplasmid (data not shown). We also performed in vitro
neutralization assays to confirm that the infectivity of the
cell lysates was mediated by newly synthesized B19
virions. Incubation of the cell lysates with neutralizing
monoclonal antibody E (Yoshimoto et al., 1991) reduced
the infectivity to undetectable levels in the IFA testing. In
contrast, incubation with a similar concentration of mono-
clonal antibody known to be non-neutralizing (monoclonal
antibody A) had no effect on infection (data not shown).
This result further supports our infection experiment,
indicating that infectious viral particles were produced
from the cells transfected with the plasmids containing
full-length B19 genome.
Finally, to confirm that the viral transcripts in the
inoculated cells was being generated from the infectious
clone, and were not due to laboratory contamination of
wild type J35 virus, we constructed the second infectious
clone (pB19-M20) that a carried a DdeI site which was
present in other B19 isolates but not in J35 virus. The
sequencing analysis of the plasmids constructed in site-
specific mutagenesis showed that full-length B19 genome
including complete ITR was stable during serial passages
in Sure2 bacteria cells, demonstrating the capacity for
manipulating and stably passaging the infectious clone.
After transfection, the viral transcripts were tested by
restriction enzyme digestion for the presence of theinfected with the cell lysates from cells transfected with infectious clones or
t-infection or post-transfection, the cell lysate was prepared by freezing and
M20-transfected cells were inoculated into the cells. The total RNAs were
PCR was performed with a primer pair of B19-1 and B19-9. The products
e-phosphatase-labeled probe. (+) and () indicate the presence or absence of
icate the respective amplicon size. (B) Detection of the B19 capsid proteins
proteins were detected in the cells inoculated with the clarified supernatant
) or pB19-N8 (B3) by using monoclonal antibody 521-5D, and fluorescein
gnification 750.
Fig. 6. RT-PCR analysis of the B19 transcripts in the UT7/Epo-S1 cells transfected with mutant infectious clone. (A) The sequence comparison of wild-type
and mutant clone at the mutant site. The numbers at the top indicate nucleotide positions in the genome of B19-J35 isolate from the 5V to 3V end. The (*)
indicates the nucleotide replacement at the position of 2285 nt. (B) RT-PCR analysis of the B19 transcripts in the UT7/Epo-S1 cells infected with natural B19
virus or infectious clone pB19-M20. The cDNA derived from the cells infected with B19 or pB19-M20 was PCR amplified by using a primer pair of B19-2255
and B19-2543. The PCR products were digested with DdeI at 37jC for 2 h and analyzed by agarose gel electrophoresis. (+) and ( ) indicate the presence or
absence of the reverse transcriptase in the reaction, respectively. The numbers on the left indicate the molecular weight standards, and those on the right indicate
respective amplicon size.
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DdeI site present in transcripts generated by wild-type
B19-J35 isolate infection, but only in the transcripts from
the cells infected with the lysate from pB19-M20-trans-
fected cells.Discussion
In this study, we have successfully cloned and sequenced
the complete parvovirus B19 genome (J35) including the
ITRs. In addition, we have been able to propagate the
plasmid in bacterial cells and use the purified plasmid as
an infectious clone, verifying that the ITRs are functional.
There has only been one previous report of the intact ITRs
of the human pathogenic parvovirus B19 (Deiss et al.,
1990). In this previous study, the genome was also cloned
in two halves and the sequence of the ITRs obtained.
However, the authors were unable to successfully ligate
the two halves of the genome together, and confirmed by
functional studies that the ITRs were correct. Other attempts
to produce an infectious clone were also unsuccessful due to
deletions in the ITR sequences (Shade et al., 1986) and the
instability of the ITRs in bacterial cells. In the present study,
we successfully cloned the full-length B19 genome by a
strategy previously used to obtain the full-length clone of
waterfowl parvoviruses that also have long ITRs (Deiss et
al., 1990; Zadori et al., 1995) using low incubation temper-
atures and Sure2 bacterial cells that are deficient in majorrecombination genes. This strategy maybe useful for cloning
other viral genomes that have a similar structure or DNA
structures that are unstable in bacterial cells.
The J35 isolate of B19 has a genome of 5592 nucleo-
tides, possessing ITRs of 381 nucleotides long. The distal
361 nucleotides of these repeats were imperfect palindromes
that form double-stranded hairpins. This normally exist in
two sequence orientations, ‘‘flip’’ or its reverse-complement
‘‘flop,’’ believed to result from hairpin transfer during
replication (Deiss et al., 1990). The complete sequence
analysis of the viral genome (J35) indicates that both the
5V and 3V ITRs have two sequence configurations analogous
to the flip and flop formats previously noted for other
parvoviruses. Although several base changes within the
ITRs were identified compared to the previous published
sequence of B19 (Deiss et al., 1990), the size and the
positions of the bubbles formed by unpaired nucleotides
in these palindromic sequences are conserved among dif-
ferent B19 isolates, suggesting an important role of these
structures in the life cycle of B19 virus. In comparison to the
previously reported B19 sequence, the hairpin of B19-J35
isolate was shorter by two nucleotides at both 5Vand 3V ends,
but this deletion does not appear to affect viral replication
and infection. Unlike other parvoviruses, the hairpins of
B19 do not appear to form a Y- or T-shape structure at the
turnaround.
Previous studies have shown that the ITRs play important
roles in the viral life cycle of other parvoviruses: they serve
as primers for the synthesis of the complementary strand of
N. Zhi et al. / Virology 318 (2004) 142–152 149viral DNA and are essential for the replication, transcription,
and packaging of virus DNA (Berns, 1990). Although it has
been suggested that the ITRs in B19 have similar functions
to those in other parvoviruses (Cotmore and Tattersall, 1984;
Deiss et al., 1990; Shade et al., 1986), the exact role of the
ITRs in viral life cycle remains to be determined due to the
lack of complete ITR sequences thus far. Our infection
studies showed that transfection of permissive UT7/Epo-S1
cells with plasmid pB19-N8 could not produce infectious
virus although the viral RNAs and proteins were detected in
the cells. Lack of secondary infection may also provide an
explanation for lower transfection efficiency of pB19-N8
compared to that of infectious clone (B19-4244). The se-
quence analysis of pB19-N8 indicated that this plasmid
contained the entire coding region of the B19 genome except
the distal 204 nucleotides in the ITRs, and indicates the
absolute necessity of the palindromic sequence and hairpin
structure for B19 replication. The confirmation of the B19
ITR sequences will now allow further studies to determine
which parts of the hairpin are responsible and necessary for
these different functions of the ITR.
Studies of parvovirus B19 have been limited, not only
because of the shortage of infectious virus, but also because
of the tropism of the virus for erythroid progenitor cells and
the limited number of cell lines that support B19 replication.
Even in these cell lines, replication is inefficient, and inoc-
ulation of virus into cells cannot be used as a method for
generating large amounts of infectious virus. Previous
attempts to transfect viral or plasmid DNA into UT7/Epo
cells had been unsuccessful using standard electroporation
conditions (Brown, unpublished observations). Only with the
Amaxa technology have we been able to get efficient (>15%)
transduction of UT7/Epo cells or the subclone used in these
studies of UT7/Epo-S1 cells. The efficiency (f15%) for
transduction of UT7/Epo cells with the infectious clone
(pB19-4244) is similar to that of B19 natural infection
(20%). As has been shown with other parvoviral infectious
clones (Samulski et al., 1982), release of the genome from the
plasmid backbone by digestion with SalI increased the
production of replicative forms of DNA detected in Southern
analysis. This increased the percentage of cells that expressed
capsid proteins, and although not formally examined,
appeared to increase the amount of infectious virus produced.
Parvovirus B19, especially in its transcription map and
limited tropism, differs in many ways from the other Parvo-
viridae, and the shortage of virus and difficulty in growing the
virus in culture has also limited the studies in the molecular
pathogenesis of the B19. However, the production of an
infectious clone and the ability to manipulate the plasmid,
as was demonstrated by the production of the pB19-M20
plasmid, will allow the genome to be systematically studied,
including the role of the small RNA transcripts (Fan et al.,
2001; Luo and Astell, 1993; St Amand and Astell, 1993), and
the phospholipase motif (Zadori et al., 2001), in infection and
replication to be determined. Such studies are already in
progress.The remarkable tissue tropism of parvovirus B19 for
human erythroid progenitor cells has prompted suggestions
that erythroid cell-specific transduction may be feasible if
recombinant B19 vectors could be developed, packaging
‘genes of interest’ in a B19 capsid. Previous studies on both
autonomous parvoviruses and the adeno-associated viruses
have indicated that successful replication and encapsidation
of parvoviral genomes require the viral ITRs sequences that
serve not only as the origin of replication (Astell, 1990;
Costello et al., 1995), but are required for encapsidation
(Wang et al., 1996; Willwand and Kaaden, 1990; Xiao et al.,
1997). Although Ponnazhagan et al. (1998) constructed a
chimeric vector system by packaging heterologous DNA
sequences within the inverted terminal repeats of AAV and
packaging the DNA inside the B19 capsid structure, their
data suggested that encapsidation was inefficient. The
length and structure of the B19 ITRs suggest that efficient
encapsidation of DNA within a B19 capsid will require
intact and functional B19 ITRs, now a possibility with our
current cloning strategy.
In summary, we now demonstrate for the first time the
production of an infectious clone of parvovirus B19, and
show that the viral genome can be excised from the plasmid,
that the viral DNA can replicate, and that infectious virus is
produced. We believe that this clone will be a useful tool in
the further research into the viral pathogenesis at the
molecular level of this human pathogen.Materials and Methods
Cells and virus
UT7/Epo-S1 cells (Shimomura et al., 1992), a subclone
of UT7/Epo previously reported to have an increased
sensitivity for parvovirus B19 (Komatsu et al., 1993), were
kindly provided by Kazuo Sugamura (Tohoku University
Graduate School of Medicine Japan). The cells were main-
tained in Iscove’s modified Dulbecco’s medium (IMDM)
containing 10% fetal calf serum (FCS), 2 U/ml recombinant
human erythropoietin (Epo, AMGEN, Thousand Oaks,
CA), and antibiotics, and were grown at 37jC with 5% CO2.
Parvovirus B19 (J35) was obtained from the serum of a
child with sickle cell anemia undergoing aplastic crisis and
sent to NIH for diagnostic purposes. The serum was found
by dot blot assay (Nguyen et al., 2002) to contain f1012
genome copies of B19 per milliliter.
Cloning and sequencing of parvovirus B19
UT7/Epo-S1 cells were infected with serum (J35) con-
taining high-titer B19 virus as previously described (Nguyen
et al., 2002). DNA was extracted by the DNAEAsy method
(Qiagen Inc., Valencia, CA) and eluted into 100 Al of water.
To obtain the coding region of B19 genome, the primer B19-
187FR (Table 1) was designed from the hairpin region of the
Table 1
List of primers used for PCR, RT-PCR, and mutagenesis
Primer Nucleotide sequence (5V–3V) Product
(bp)
Usage
B19-187FR cgc-ttg-tct-tag-tgg-cac-gtc-aac 5222 clone coding
region
B19-1F cca-cga-tgc-agc-tac-aac-tt clone ITR
B19-186R- gtg-agc-gcg-ccg-ctt-gtc-tta-gtg 186
B19-181F gtg-agc-gcg-ccg-ctt-gat-ctt-agt clone ITR
B19-1372R aac-ttc-cac-tgt-gac-tac-tg 1195
B19-181F gtg-agc-gcg-ccg-ctt-gat-ctt-agt clone ITR
B19-4899F aac-acc-aca-ggc-atg-gat-ac 518
Cmcf catttgtcggaagctcagtttcctccgaag creation mutant
clone
Cmcr cttcggaggaaactgagcttccgacaaatg
B19-2255 gga-acc-agt-tca-gga-gaa-tca amplify mutant
site in pM20
B19-2543 tgg-cag-cta-cat-cgc-acc-aa 228
N. Zhi et al. / Virology 318 (2004) 142–152150virus using sequences available in GenBank (19-HV;
AF162273). The high-fidelity long PCR amplification was
performed using the single primer B19-187FR with the HF-2
polymerase kit (BD Biosciences, Palo Alto, CA) with 25
cycles of amplification (94jC, 15 s; 55jC, 30 s; 72jC 4 min;
followed by 72jC extension for 7 min). The amplicon was
cloned by blunt ligation into a pCR-Blunt II TOPO (Invi-
trogen-Life Technologies, San Diego, CA) and transformed
into Top10 cells (Invitrogen-Life Technologies).
Colonies were screened by hybridization with a 32P-
random-primed B19 probe obtained from pYT103 as pre-
viously described for dot blot hybridization (Nguyen et al.,
2002), and positive clones confirmed by sequencing the
plasmids using BigDye terminator cycle sequencing (ABI-
Perkin Elmer, Foster City, CA). The full-length sequences of
both strands were obtained by primer walking.
To obtain the complete hairpin sequence, primers were
designed from the cloned sequence and from B19 sequences
available in GenBank (Table 1). PCR amplification was
performed using ExTaq polymerase with 30 cycles of
amplification. The PCR products were ligated into PCR2.1
TOPO by TA cloning (Invitrogen-Life Technologies), Top10
cells transformed, and the products sequenced as above.
All DNA sequences, and the amino acid sequence of
open reading frames, were analyzed using Lasergene soft-
ware (DNAStar, Inc., Madison, WI). DNA pairwise homol-
ogy was determined by Lipman–Pearson method with a
Ktuple of 2, gap penalty of 4, and deletion penalty of 12.
Multiple sequence alignments were determined using the
Megalign program, using the Clustal method with a gap
penalty of 10 and gap length penalty of 10.
Construction of an infectious clone
The strategy for cloning the full-length B19 genome is
illustrated in Fig. 1A. B19 DNA was purified from 50 Al of
viremic serum (J35) using the High Pure Viral Nucleic Acid
Kit (Roche, Indianapolis, IN): a total off1.5 Ag of double-
stranded B19 DNA was obtained. Double-stranded viralDNA (0.5 Ag) was digested with BamHI and both resulting
fragments were ligated into BamHI–StuI-digested pProEX
HTb vector (Invitrogen-Life Technologies). The ligated
products were electroporated into Sure2 cells (Stratagene,
La Jolla, CA) using a BTX electroporator, then the bacteria
were immediately plated and incubated overnight at 30jC.
The resultant colonies were screened for inserts. To reduce
the vector size and eliminate undesired restriction sites,
clones that contained the right end of the genome were
digested with EcoRV and religated (pB19-42d6). The insert
of the plasmid, together with the insert of the left end
containing plasmid (pB19-44) was completely sequenced.
To create full-length clones, pB19-44 was digested with
BamHI and Ecl136II and the fragments containing the left
end of the genome were cloned into the BamHI–EheI site of
the pB19-42d6 plasmid resulting in pB19-4244 (Fig. 1B2).
To test the stability of the plasmid containing full-length
B19 genome, the plasmid 4244 was digested with BamHI
and religated, and then transformed into bacteria Sure2 cells.
After incubation at 30jC overnight, 18 colonies were picked
up from the plates and the bacteria were propagated at
30jC. The plasmids were purified and mapped with restric-
tion digestion with HindIII, BssHII, and SalI. The fragments
were then analyzed by agarose electrophoresis.
Creation of a mutant clone
To confirm that the infectious clone could generate
infectious virus, a second infectious clone was produced
by site-directed mutagenesis. The cytosine at position 2285
(B19-J35 isolate) was replaced with a thymine to generate a
recognition site for restriction enzyme DdeI to produce a
naturally existing variant of B19 (B19-Wi isolate, GenBank
M4682). The full-length plasmid pB19-4244 was cut with
NheI and the 5V overhang filled in using T4 polymerase. The
linearized plasmid was redigested with XbaI, the B19
fragment (from nucleotide 1247 to 3423 in the genome of
B19-J35 isolate) ligated into an XbaI–Ecl136II-digested
pBluescriptII KS+ cloning vector (Stratagene), and site-
specific mutagenesis (C2285T) was performed using the
Quickchange Site-directed Mutagenesis Kit (Stratagene)
and primers CMCf and CMCr (Table 1). To eliminate an
undesired XbaI restriction site in the vector sequence of the
plasmid pB19-4244, the plasmid was digested with
Ecl136II–XhoI enzymes, the XhoI overhang was blunted
with T4 polymerase, and the plasmid was religated (plasmid
pB19-4244d, Fig. 1B3). The plasmid with the B19 fragment
containing C2285T mutation was digested with MscI–XbaI
and the B19 fragment was ligated into the MscI–XbaI-
digested pB19-4244d plasmid resulting in the pB19-M20
clone (Fig. 1B4).
Transfection of UT7/Epo-S1 cells
The conditions and reagents for transfecting plasmid
DNA into UT7/Epo-S1 cells were first optimized using
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encodes farnesylated enhanced green fluorescent protein
(EGFP). Cells were examined at daily intervals for
expression of EGFP by UV microscopy and by FACS
analysis. Conditions that gave the maximum number of
cells expressing EGFP with minimum cytotoxicity were
chosen. For subsequent experiments, UT7/Epo-S1 cells
were transfected using the AMAXA Cell Line Nucleofector
kit R according to manufacturer’s instruction (AMAXA
Biosystems Inc., Nattermannallee, Germany). The cells
were harvested at various times post-transfection and used
for DNA, RNA, and immunofluorescence studies. For
infection studies, cells were harvested at 72 h post-trans-
fection, washed free of inoculums using fresh culture
medium, and cell lysate prepared by three cycles of
freeze–thawing. After centrifugation at 10,000  g for 10
min, the clarified supernatant was treated with RNase (final
concentration of 1 U/Al, Roche) and collected for further
infections.
RT-PCR for B19 transcripts
Total RNAwas extracted from the UT7/Epo-S1 cells (2 
105) using RNA STAT60 (Tel-Test Inc., Friendswood, TX).
Residual DNA was removed by DNAse I treatment (final
concentration, 90 U/ml) for 15 min at room temperature.
RNA was converted to cDNA with random hexamers and
SuperScript II and RT-PCR for the spliced capsid transcripts
was performed with primers B19-1 and B19-9 as previously
(Nguyen et al., 2002).
To exclude the possibility that the transcripts detected
were derived from the laboratory contamination of B19 viral
RNA, the cDNA derived from the pM20-transfected cells
were PCR amplified by using a primer pair of B19-2255 and
B19-2543 (Table 1), which targeted on the region contain-
ing the site of mutagenesis (C2285T). After purification
using QIAquick PCR Purification Kit (Qiagen Inc.), the
PCR products were digested with DdeI at 37jC for 2 h.
Indirect fluorescent antibody assay for B19 capsid proteins
Infected or transfected cells were harvested and cyto-
centrifuged (1500 rpm for 8 min in a Shandon cytospin 2
cytocentrifge). The cells were fixed in acetone/methanol
(1:1) at  20jC for 5 min and washed twice in phos-
phate-buffered saline (PBS) containing 0.1% fetal bovine
serum, and incubated with a mouse monoclonal antibody
specific to B19 capsid proteins (521-5D, a kind gift of Dr
Larry Anderson, CDC) in PBS with 10% fetal calf serum
for 1 h at 37jC. After washing the slides twice in PBS,
the slides were incubated with fluorescein isothiocyanate-
labeled goat anti-mouse IgG antibody (Jackson Immu-
noResearch Laboratories, Inc., West Grove, PA) in PBS
with 10% fetal calf serum and Evans Blue as a counter-
stain for 30 min at 37jC, washed, and examined by UV
microscopy.Southern blot analysis of B19 DNA
DNA was extracted from B19-infected UT7/Epo-S1
cells (5  105) as previously described (Shimomura et
al., 1992). Briefly, 5  105 cells were incubated with 100
mM NaCl, 10 mM Tris–HCl pH 7.5, 0.5% sodium
dodecylsufate, 5 mM EDTA, and 200 Ag/ml proteinase K
overnight at 37jC followed by phenol-chloroform extrac-
tion. For some experiments, high- and low-molecular-
weight DNA was separated by the Hirt (1967) method.
Purified DNA (400 ng) was digested with 20 U of BamHI
(single cut in B19) or EcoRI (no cut in B19) at 37jC for 4
h, the fragments were then separated by agarose electro-
phoresis, transferred to a nylon membrane (Nylon+, Amer-
sham), and hybridized with a 32P-random-primed probe of
the complete B19 coding region as previously described
(Shimomura et al., 1992).
Infection of UT7/Epo-S1 cells and Neutralization assay
For infection studies, 2  104 of UT7/Epo-S1 cells in 10
Al IMDM were mixed with an equal volume of sample or
positive control (J35 serum diluted to contain 108 B19
genome copies) and incubated at 4jC for 2 h to allow for
maximum virus–cell interaction. The cells were then diluted
to 2  105 cells/ml in the culture medium, and incubated at
37jC in 5% CO2. Cells were harvested at 3 days post-
infection and tested for evidence of infection by detection of
viral transcripts and protein expression.
In vitro neutralization assays were performed to test
whether neutralizing monoclonal antibodies against parvo-
virus B19 capsids were able to block the infection caused by
the cell lysates of transfected cells. The clarified cell lysates
prepared from the transfected cells were mixed with mono-
clonal antibody A and E (Yoshimoto et al., 1991) at a
dilution of 1:10, and incubated at room temperature for 2 h.
The anti-B19 monoclonal antibody A without neutralizing
activities was used as control. The infection studies were
performed as described above.
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